Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973253 | 0.82 | APP (1.00) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL4067458 | 0.75 | APP (0.78) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL14527090 | 0.74 | ALDH1A1 (0.49) | APPALDH1A1HPGDARSMN1; SMN2 | |
| SCHEMBL31149035 | 0.74 | APP (0.75) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL22834155 | 0.74 | APP (0.75) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL23795211 | 0.74 | APP (0.75) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL397364 | 0.74 | ALDH1A1 (0.43) | APPHSD17B1HSD17B2ALDH1A1KDM4E | |
| SCHEMBL29668171 | 0.74 | APP (0.75) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL28339390 | 0.74 | APP (0.75) | APPHDAC6HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL4715808 | 0.74 | HSD17B2 (0.41) | HSD17B1HSD17B2ALDH1A1HPGDPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448561-B1 | BETA 3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7241772-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1421078-B1 | INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-7071208-B2 | β3 Adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20050020618-A1 | Beta 3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1448561-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421078-A1 | BETA-3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| WO-2003044017-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | APP 1912/4885HDAC6 2678/4885HSD17B1 172/4885 |
| US-20050020618-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | APP 1912/4885HDAC6 2678/4885HSD17B1 172/4885 |
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | APP 1654/4885HDAC6 1614/4885HSD17B1 290/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | APP 1784/4885HDAC6 1862/4885HSD17B1 229/4885 |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | APP 1912/4885HDAC6 2678/4885HSD17B1 172/4885 |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | APP 1931/4885HDAC6 2875/4885HSD17B1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.